Beat The Denominator

Consider Hims & Hers (HIMS) as a buying opportunity after its significant drop, as its new lab testing service is a major growth catalyst. The telehealth company LifeMD (LFMD) is presented as an extremely cheap value play after a nearly 70% drawdown from its highs. As a key supplier for NVIDIA, Super Micro Computer (SMCI) is considered a "dirt cheap" way to invest in AI infrastructure following its 45% price decline. In the beaten-down Bitcoin mining sector, Marathon Digital (MARA) is a top pick as it trades at a discount to the value of the Bitcoin it holds. For direct exposure to Bitcoin at a discount, Strategy Development Co. (STRT) is highlighted as a "blue chip" choice, currently trading below the market value of its net assets.

Consider buying crypto-related stocks like MicroStrategy (MSTR) and Marathon Digital (MARA), which are trading at a 5% and 15% discount to their respective Bitcoin holdings. For long-term investors, Hims & Hers (HIMS) is presented as a high-conviction opportunity to invest in healthcare disruption following its recent sell-off. The sharp drop in Oscar Health (OSCR) to around $14 is viewed as an unwarranted overreaction, creating a potential entry point for investors. The current weakness in Tesla (TSLA) is seen as a buying opportunity for those who believe in its long-term vision for AI and robotics. Watch for upcoming NVIDIA (NVDA) earnings, which could act as a major positive catalyst for the entire market.

MicroStrategy (MSTR) presents a significant buying opportunity as it currently trades at a discount to the value of its Bitcoin holdings, a rare occurrence. For investors bullish on Bitcoin, consider purchasing MSTR common stock or long-term options like 2028 LEAPs to gain this undervalued exposure. The price drop is attributed to a temporary, market-wide liquidity issue, not a problem specific to the company. This broader sell-off may also offer entry points into other beaten-down sectors like hyper-growth and AI stocks. Active traders should note the recurring pattern of Bitcoin falling during US market hours before rebounding strongly overnight.

CorMedix (CRMD) presents a potential buying opportunity as the stock appears undervalued despite strong Q3 earnings and rapid growth of its DefenCath product. The company is profitable, has no debt, and trades at a low forward valuation of just 3.5 times its projected 2025 adjusted EBITDA. The recent acquisition of Melinta Therapeutics strengthens its position as a specialized anti-infection company with expected cost savings of over $30 million. While a key risk is the CMS reimbursement negotiation for DefenCath in January, this concern may already be priced into the stock. The disconnect between CRMD's strong fundamentals and its current share price could represent an attractive entry point for long-term investors.

Consider MicroStrategy (MSTR), which is viewed as deeply undervalued and has a near-term catalyst from an expected large Bitcoin purchase around Thursday. For deep value, AmpereX (EMPD) offers a way to acquire Bitcoin at a 41% discount, while the market is ignoring both the $100M+ Bitcoin treasury and the core tech business of KULR Technology (KULR). A unique opportunity exists with Upexi (UPXI) and DeFi Technologies (DFDV), which allow you to buy Solana and Ethereum at steep discounts while earning yields of 7-10% through staking. To specifically target Ethereum at a discount, Sharplink Gaming (SBET) is trading 17-20% below the value of its ETH holdings. The core investment thesis is to purchase these crypto-proxy stocks for less than the value of the digital assets on their balance sheets.

Consider buying Nebius (NBIS), an undervalued AI infrastructure company whose recent stock drop presents a significant buying opportunity. The company's growth is validated by massive contracts, including a $3 billion deal with Meta (META) and a $19 billion deal with Microsoft (MSFT). Management forecasts a potential 10x to 16x revenue increase by the end of 2026, driven by explosive demand for AI compute. The current stock price may not reflect the hidden value of its significant stakes in private tech companies ClickHouse and AVRide, which could be unlocked through future IPOs. With the stock trading at a low 4 times forward sales, the current valuation is seen as an attractive entry point for this hyper-growth story.

Consider buying MicroStrategy (MSTR) common stock as a long-term holding due to its aggressive and ongoing strategy of accumulating Bitcoin. The current price weakness in Bitcoin (BTC), driven by low market liquidity, may present an accumulation opportunity for long-term believers. A potential Federal Reserve rate cut in December is a key catalyst to watch, as it could provide a significant tailwind for risk assets like BTC. Monitor the success of new investment products like MicroStrategy's Stretch and Strive's SATA, which are funneling new capital into Bitcoin. Finally, growing real-world adoption, such as Square (SQ) enabling direct Bitcoin payments, continues to strengthen the asset's fundamental value.

Consider MicroStrategy (MSTR) as a bullish investment due to its aggressive strategy of acquiring Bitcoin with company stock. A potential short squeeze could soon drive the MSTR stock price higher, as a major short-seller has reportedly exited their position. Investors should watch for the company's next filing to confirm a new purchase of over 500 Bitcoin, which would validate this bullish thesis. Separately, Bitcoin (BTC) could see a near-term price increase from potential stimulus checks and an anticipated end to the government shutdown within the next 10 days. These events are expected to increase overall market liquidity, which is historically positive for risk assets like crypto.

Consider a short-term trade in Bitcoin (BTC), as a potential price increase is anticipated this coming Thursday due to a planned $620 million purchase by MicroStrategy. For a longer-term investment, look at MicroStrategy (MSTR), as a prominent short-seller has recently closed their position, signaling a bullish outlook. MSTR offers leveraged exposure to Bitcoin by continuously raising capital to acquire more, amplifying potential returns for shareholders. The stock is argued to be undervalued, presenting an opportunity for investors who believe it should trade at a significant premium to its underlying Bitcoin holdings. Therefore, MSTR can be an attractive alternative to holding Bitcoin directly or through an ETF, especially for those seeking amplified returns in tax-advantaged accounts.

The 45% sell-off in Celsius Holdings (CELH) is viewed as a major overreaction and a buying opportunity, as its fundamental growth remains strong. Similarly, Oddity Tech (ODD) is presented as a high-quality beauty stock that is significantly undervalued after falling 47% on little news. Consider watching Hims & Hers Health (HIMS) for a potential catalyst from a major announcement scheduled for November 13th. For direct exposure to Bitcoin, MicroStrategy (MSTR) is expected to make a large purchase of the cryptocurrency around mid-November. Lastly, the recent pullback in Meta Platforms (META) offers a chance to invest in its highly profitable core business while getting the long-term AR/VR growth potential for free.

Consider MicroStrategy (MSTR), as the company is raising significant capital with the intent to purchase approximately 6,000 more Bitcoin, a near-term catalyst the market is currently ignoring. The significant sell-off in NVIDIA (NVDA) is viewed as a market-driven buying opportunity, not a reflection of its strong fundamentals in the AI sector. Similarly, the recent drop in Tesla (TSLA) stock presents a potential entry point, as it seems disconnected from the company's positive progress in robotics. With the Crypto Fear and Greed Index indicating "Extreme Fear," this may be an opportune time to accumulate long-term positions in Bitcoin (BTC). Overall, the current market fear is creating potential discounts in high-growth technology stocks for investors with a long-term horizon.

The recent 28% drop in Celsius Holdings (CELH) presents a major buying opportunity, as the market misunderstood a termination cost that is actually being funded by its partner, Pepsi. LifeMD (LFMD) is a deeply undervalued telehealth company whose recent drop on a minor accounting issue creates a significant entry point for a business growing at 32%. Consider KULR Technology Group (KULR) as a deep value play, where its current market cap is almost entirely covered by its Bitcoin holdings, essentially offering its high-growth space and robotics business for free. For investors interested in the beauty sector, Oddity Tech (ODD) is presented as a stronger choice over e.l.f. Beauty (ELF) due to its superior direct-to-consumer model and lack of China tariff risk. Watch for a potential announcement from MicroStrategy (MSTR) on Monday regarding new Bitcoin purchases, which may have been funded by recent share offerings near the $100 level.

LifeMD (LFMD) has become a more compelling investment after selling its non-core WorkSimply division for $46 million. This move transforms LFMD into a pure-play telehealth company, revealing a much higher core business growth rate of around 32%. The stock appears significantly undervalued compared to its larger competitor, Hims & Hers (HIMS). Based on the analyst's valuation metric, LFMD trades at a substantial discount to HIMS, suggesting significant upside potential. The upcoming Q3 earnings report is a key catalyst to watch, as it will be the first to reflect the company's new, more focused structure.

Consider MicroStrategy's preferred stock, STRC, as a stable-value investment designed to trade around $100, offering a managed yield as an alternative to money market funds. The capital raised from instruments like STRC is used to buy more Bitcoin, which is bullish for MicroStrategy (MSTR) common stock as it may reduce future shareholder dilution. MSTR remains a primary way to gain leveraged exposure to Bitcoin, as the company's core strategy is to continuously accumulate the asset. This corporate strategy creates a systematic, long-term buying pressure for Bitcoin (BTC) by siphoning capital from traditional financial markets. Therefore, investors with a long-term bullish view on Bitcoin should view MicroStrategy's financing activities as a significant positive catalyst for both MSTR and BTC.

The recent drop in Hims & Hers (HIMS) is viewed as a significant buying opportunity, as the market is ignoring its 49% revenue growth and upcoming product reveal. Similarly, the dip in Nvidia (NVDA) presents an attractive entry point, with analysts seeing it as a cheap stock poised for massive revenue growth in the AI sector. Consider MicroStrategy (MSTR) as a strategic proxy for Bitcoin, as it has demonstrated relative strength and is using innovative financing to acquire more assets. The decline in Tesla (TSLA) is seen as a macro-driven overreaction, not a reflection of fundamental risk. In contrast, investors should be cautious with Palantir (PLTR), as its high valuation may present a risk despite strong company performance.

European investors should consider MicroStrategy's new security, STRE, which offers an attractive 10% annual yield paid in Euros. Look to purchase STRE on the Luxembourg Stock Exchange at or below its expected IPO price of €100 per share for potential capital appreciation towards a €127 target. The investment is well-collateralized, with a safety buffer designed to withstand a Bitcoin price drop of over 70%. This innovative financing is a bullish catalyst for MicroStrategy (MSTR) as it strengthens its core strategy of acquiring Bitcoin. The offering will create significant buying pressure for Bitcoin (BTC), with proceeds expected to fund the purchase of 7,000-8,000 BTC.

Hims & Hers Health (HIMS) is presented as a compelling investment opportunity following outstanding Q3 results that saw revenue growth rebound to 49% year-over-year. The company's profits are growing even faster than its revenue, demonstrating strong operational efficiency and a successful shift to high-value personalized subscriptions. The core thesis is that HIMS is significantly undervalued by the market and should be valued more like a high-growth software company. With its strong performance, the stock price could potentially grow in line with its revenue, suggesting a potential upside of nearly 50% per year. Future growth catalysts to watch include the launch of new treatments for menopause and testosterone.

The Real Brokerage (REAX) is a high-conviction growth opportunity, as it is rapidly gaining market share in a weak housing market. The recent price drop to around $3.63 is viewed as a market overreaction, presenting a potential buying opportunity for this debt-free company. Similarly, TG Therapeutics (TGTX) is considered a compelling investment after its price fell despite strong earnings and a new stock buyback program. The company holds a functional duopoly with its Multiple Sclerosis drug, Briumvi, which has patent protection until 2042, making it a potential long-term cash generator. Both small-cap stocks are viewed as being unfairly sold off, offering a chance to invest in fundamentally strong businesses at a discount.

Current weakness in Bitcoin (BTC) is viewed as a short-term buying opportunity caused by market manipulation, not a change in long-term fundamentals. With positive macro factors like upcoming Quantitative Easing and potential rate cuts on the horizon, this could be an ideal time to accumulate BTC. For investors seeking a stock-based proxy, MicroStrategy (MSTR) is showing relative strength and acts as a leveraged play on Bitcoin's price. The company continues to aggressively acquire more coins, reinforcing its strategy. Consider the current dip as a strategic entry point for both BTC and its equity proxy MSTR for a long-term bullish outlook.

Consider MicroStrategy's preferred stock-like instruments for their unique tax-advantaged dividends. These investments pay a "Return of Capital" (ROC), meaning your dividends are 0% taxed until your initial investment is fully paid back. The analysis identifies strike as the most compelling option among the available instruments due to its superior return potential. Strike offers a high tax-equivalent yield of 21%, making it particularly attractive for investors in higher tax brackets. To realize this tax advantage, these instruments should be held in a taxable brokerage account, not a tax-deferred one like an IRA.